FDA Approved: OCTREOSCAN — Supplemental Application (Curium US LLC)

View source ↗

Summary

FDA documents a supplemental approval application for OCTREOSCAN (Indium-111 pentetreotide) submitted by Curium US LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumors
• Gastroenteropancreatic Neuroendocrine Tumors
• Neuroendocrine Tumors

Drugs mentioned

• OCTREOSCAN (Indium-111 pentetreotide)

Snippet

SUPPL AP for OCTREOSCAN (INDIUM IN -111 PENTETREOTIDE)